Essilor agrees to $22M settlement over kickback charges
By 
Aaron Nicodemus2022-08-24T19:06:00
Essilor, a manufacturer and distributor of optical lenses and equipment, will pay $22 million to settle allegations it paid kickbacks to spur sales in violation of the False Claims Act (FCA).
Dallas-based Essilor International and its subsidiaries Essilor of America, Essilor Laboratories of America, and Essilor Instruments USA conducted an incentive scheme from 2011-16 that paid optometrists and ophthalmologists to encourage patients to choose Essilor products, the Department of Justice (DOJ) said Tuesday in a press release. The alleged scheme violated the anti-kickback statute of the FCA.
Essilor will pay $16.4 million to the federal government and $5.6 million to states whose Medicaid programs were affected by the alleged misconduct, according to the settlement agreement.
THIS IS MEMBERS-ONLY CONTENT
You are not logged in and do not have access to members-only content.
If you are already a registered user or a member, SIGN IN now.
Related articles
-
News BriefTeva Pharma to pay $450M to settle kickback, price-fixing allegations
Generic drug giant Teva Pharmaceuticals has agreed to pay $450 million to settle two cases brought by the Department of Justice (DOJ), including one alleging that co-pays it made on behalf of Medicare patients constituted illegal kickbacks, and a second action for alleged generic drug price fixing.
-
ArticlePharma, whistleblower lessons learned from $900M Biogen settlement
Experts discuss the ramifications of Biogen’s $900 million settlement for False Claims Act violations, including the $266.4 million whistleblower bounty in the case believed to be the largest single award under any government program.
-
ArticleBiogen finalizes $900M settlement in false claims whistleblower suit
Biogen finalized a $900 million settlement concerning alleged kickbacks it paid to doctors to induce them to prescribe the company’s drugs and not those of its competitors.
More from Regulatory Enforcement
-
ArticleU.K. competition regulator ‘very likely’ to use new enforcement powers despite government’s pro-growth agenda
New powers granted to the U.K.’s main competition watchdog will result in greater scrutiny, tougher enforcement, and a stark warning for companies to review their sales and marketing promotions—especially since some practices have been pushed firmly into the spotlight thanks to legislation that came into effect last year.
-
ArticleSEC enforcement priorities revert back to basics
Recent pronouncements made by the U.S. Securities and Exchange Commission leadership, alongside the recent overhaul of the SEC Enforcement Manual, collectively signal a back-to-basics enforcement approach that appears beneficial for companies in their dealings with the agency.
-
ArticleFCA drive to reduce its investigation costs likely to add to compliance burden for smaller firms, warn experts
The U.K. financial regulator’s move towards “impactful deterrence” could see smaller and mid-size firms come increasingly under the spotlight as the watchdog aims to tackle market-wide concerns instead of primarily focusing on large players capable of doing the most harm.